89371-37-9

Basic information

• Product Name: Imidapril
• Synonyms: (s)-3-(n-((s)-1-ethoxycarbonyl-3-phenylpropyl)-l-alanyl)-1-methyl-2-oxoimidazoline-4-carboxylic acid;IMIDAPRIL;lmidaprfil;(4S)-3-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic Aci;4-Imidazolidinecarboxylic acid, 3-[(2S)-2-[[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, (4S)-;4-Imidazolidinecarboxylic acid, 3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, [4S-[3[R*(R*)],4R*]]-;(4S)-3-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-4-imidazolidinecarboxylic Acid Hydrochloride;(4S)-3-[(2S)-2-[N-[(1S)-1-(Ethyoxycarbonyl)-3-phenylpropyl]amino]propionyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
• CAS NO: 89371-37-9
• Molecular Formula: C₂₀H₂₇N₃O₆
• Molecular Weight: 405.44
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 89371-37-9.mol
• Article Data: 3

Chemical Properties

• Melting Point: 195-197°C
• Boiling Point: 577 °C at 760 mmHg
• Flash Point: 302.8 °C
• Appearance: white solid
• Density: 1.266 g/cm³
• Vapor Pressure: 3.71E-14mmHg at 25°C
• Storage Temp.: -20°C Freezer
• PKA: 2.44±0.20(Predicted)
• CAS DataBase Reference: Imidapril(CAS DataBase Reference)
• NIST Chemistry Reference: Imidapril(89371-37-9)
• EPA Substance Registry System: Imidapril(89371-37-9)

Safety Data

• Hazardous Substances Data: 89371-37-9(Hazardous Substances Data)

Usage

Description

Imidapril is a new ACE inhibitor launched in Japan as a once-daily therapy for hypertension. Its active metabolite has more potent inhibitory effects on all tissue ACES from spontaneously hypertensive rats (SHRs) and Wistar Kyoto rats (WKYs) than many other ACE inhibitors including enalapril and captopril. It has a very long duration of action. In strokeprone spontaneously hypertensive rats (SHRSP), imidapril is effective in stroke prevention at a considerably lower dose than enalapril. This stroke preventive effect has been suggested to be primarily by an indirect mechanism related to the amelioration of kidney dysfunction.

Chemical Properties

White Solid

Uses

Angiotensin converting enzyme (ACE) inhibitor. Antihypertensive

Brand name

Tanatril; Novarok

InChI:InChI=1/C20H27N3O6.ClH/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28;/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26);1H/t13-,15-,16-;/m0./s1

Upstream product

• 89371-36-8 benzyl (4S)-1-methyl-3-{(2S)-2-[N-((1S)-1-ethoxycarbonyl-3-phenylpropyl)amino]propionyl}-2-oxoimidazolidine-4-carboxylate 
• 89371-38-0 tert-butyl (4S)-1-methyl-3-{(2S)-2-[N-((1S)-1-ethoxycarbonyl-3-phenylpropyl)amino]propionyl}-2-oxo-imidazolidine-4-carboxylate 
• 117605-23-9 tert-Butyl (4S)-3-<(2S)-2-amino>propionyl>-1-methyl-2-oxoimidazolidine-4-carboxylate Hydrogenmaleate 

Downstream Products

• 64-17-5 ethanol 
• 89371-44-8 (4S)-1-methyl-3-{(2S)-2-[N-((1S)-1-carboxy-3-phenylpropyl)amino]propionyl}-2-oxo-imidazolidine-4-carboxylic acid 

Relevant articles and documents

USE OF SUBSTITUTED 2 PHENYLBENZIMIDAZOLES AS MEDICAMENTS

The present invention relates to the use of a substituted 2-phenylbenzimidazole of formula I wherein R1, R2, R3, R 4, R5 and m have the meanings given in the claims, for the preparation of a medicament for the treatment or prevention of diseases involving glucagon receptors, as well as new compounds of formula I wherein R1 is a group of formula

ANTIHYPERTENSIVE 2-OXO-IMIDAZOLIDINE DERIVATIVES

Novel 2-oxo-imidazolidine derivative of the formula: STR1 wherein R 1 is lower alkyl or phenyl-lower alkyl, R 2 is lower alkyl, R. sup.3 is alkyl of one to 12 carbon atoms or phenyl-lower alkyl and R 4 is hydrogen or lower alkyl, and a pharmaceutically acceptable salts thereof are disclsoed. Said compounds (I) and salts thereof are useful as hypotensive agents.